Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resist… (NCT00124020) | Clinical Trial Compass
CompletedPhase 3
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
Israel771 participantsStarted 2005-01
Plain-language summary
Study 0019 (NCT00124020) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Clinical signs and symptoms consistent with pneumonia acquired after at least 48 hours of continuous stay in an inpatient acute or chronic care facility or acquired within 7 days after being discharged from a hospitalization of greater than or equal to 3 days duration.
Exclusion Criteria:
* Received more than 24 hours of potentially effective systemic (IV, IM or PO) antibiotic therapy for Gram-positive pneumonia immediately prior to randomization.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial compared telavancin to vancomycin specifically for hospital-acquired pneumonia caused by MRSA — if my pneumonia is also caused by MRSA, is telavancin something worth considering for me, or is vancomycin still the standard approach my team would recommend?
2Since this was a completed Phase 3 trial measuring clinical response, what did the results actually show about how well telavancin worked compared to vancomycin, and did one treatment perform better for certain types of patients?
3I've heard vancomycin has been used for MRSA for a long time — based on what this trial found, is there a meaningful safety or effectiveness reason to choose telavancin over vancomycin in my specific situation?
4This trial focused on hospital-acquired pneumonia, which can be very serious — are there particular patient groups, like those with kidney problems, where one drug was shown to be safer than the other in this study?
5Since this trial is now completed, is telavancin an approved treatment option that's actually available to me today, or would I need to look into other ways to access it?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Clinical Response
Timeframe: 7-14 days following end of antibiotic treatment